Geographically, DCB has a diversified pan-India presence with a stronger footprint across western and southern India, while continuing to expand selectively into underpenetrated markets.
Dr Lal PathLabs' share price jumped 8 per cent to a fresh 52-week high of ₹1,893.65 on the BSE today. The company has posted a better-than-expected Q1 show, prompting analysts to raise target prices.
Care Ratings expects Dr Lal PathLabs' revenue to grow by 11-12 per cent per annum in the near-to-medium term driven by organic demand growth, its expanding geographical presence and new initiatives.
Metropolis Healthcare share hit a 52-week high of ₹574.45, surging 14 per cent in trade. Thyrocare soared 12 per cent to ₹526.10, while Vijaya Diagnostic Centre gained 7 per cent to ₹1,298.45.
Diagnostics firm reports profit decline due to prior-year tax benefit, while revenue growth remains strong on higher sample volumes and improved test mix
Dr Lal PathLabs is focusing on innovation, including new wellness packages and high-end, super-speciality tests, with a focus on capturing prescription shares
Diagnostic chains are expanding laboratories, integrated centres and collection networks as demand grows for preventive, genomics-led and precision testing across India
Technical charts show Escorts, Hudco, Dr Lal PathLabs, Force Motors and Godrej Consumer were trading above the higher-end of the Bollinger Bands on the daily scale; and can potentially rally up to 23%
Domestic brokerage firm Nuvama analysts forecast a modest sequential slowdown but a healthy ~17 per cent year-on-year (Y-o-Y) Ebitda growth, led by hospitals and diagnostics.
Dr. Lal Path Labs shares rose 3.2 per cent on Wednesday, after it became the first laboratory in the country to adopt a deep learning-based AI module to detect lymph node metastas
